With box warnings

Without box warnings

Branded

Generic

2 results

fasenra
(Benralizumab)
AstraZeneca Pharmaceuticals LP
Usage: FASENRA is indicated for the add-on maintenance treatment of severe asthma in patients aged 6 years and older with an eosinophilic phenotype and for treating eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It is not for acute bronchospasm relief.
nucala
(mepolizumab)
GlaxoSmithKline LLC
Usage: NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.

Medications for Eosinophilic Granulomatosis With Polyangiitis

fasenra